Par Pharmaceutical halts shipment of generic Flonase

By Lisa Kerner

Erie, Pa., Feb. 24 - Par Pharmaceutical Cos. Inc. said the U.S. District Court for the District of Maryland granted GlaxoSmithKline its motion for a temporary restraining order to set aside the Food and Drug Administration's final decision approving an abbreviated New Drug Application for a generic version of Flonase (fluticasone propionate) nasal spray.

While the temporary restraining order is pending - it expires March 6- any FDA approval or future FDA approval allowing the marketing and sale of a generic version of GlaxoSmithKline's Flonase nasal spray is and will be suspended, according to a company news release.

Par said as a result it has halted all shipments of fluticasone propionate nasal spray and will take necessary steps to comply with this order.

Par, based in Spring Valley, N.Y., develops, manufactures and markets generic drugs and branded pharmaceuticals for specialty markets.

© 2015 Prospect News.
All content on this website is protected by copyright law in the U.S. and elsewhere. For the use of the person downloading only.
Redistribution and copying are prohibited by law without written permission in advance from Prospect News.
Redistribution or copying includes e-mailing, printing multiple copies or any other form of reproduction.